# Odd Erik Johansen

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/odd-erik-johansen/

## Facts

| Field | Value |
| --- | --- |
| Citations | 26,812 |
| Field | Diabetes Treatment and Management |
| h-index | 40 |
| i10-index | 87 |
| OpenAlex ID | https://openalex.org/A5008842761 |
| ORCID iD | https://orcid.org/0000-0003-2470-0530 |
| Works | 225 |

## Researcher papers

- [Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes](https://scholariq.org/papers/empagliflozin-cardiovascular-outcomes-and-mortality-in-type-2-diabetes/)
- [Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes](https://scholariq.org/papers/empagliflozin-and-progression-of-kidney-disease-in-type-2-diabetes/)
- [Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus](https://scholariq.org/papers/renal-hemodynamic-effect-of-sodium-glucose-cotransporter-2-inhibition-in/)
- [Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk](https://scholariq.org/papers/effect-of-linagliptin-vs-placebo-on-major-cardiovascular-events-in-adults-with/)
- [Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME <sup>®</sup> trial](https://scholariq.org/papers/heart-failure-outcomes-with-empagliflozin-in-patients-with-type-2-diabetes-at/)
- [How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial](https://scholariq.org/papers/how-does-empagliflozin-reduce-cardiovascular-mortality-insights-from-a-mediation/)
- [Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes](https://scholariq.org/papers/effect-of-linagliptin-vs-glimepiride-on-major-adverse-cardiovascular-outcomes-in/)
- [Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes](https://scholariq.org/papers/effects-of-empagliflozin-on-blood-pressure-and-markers-of-arterial-stiffness-and/)
- [The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus](https://scholariq.org/papers/the-effect-of-empagliflozin-on-arterial-stiffness-and-heart-rate-variability-in/)
- [Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial](https://scholariq.org/papers/empagliflozin-reduced-mortality-and-hospitalization-for-heart-failure-across-the/)
- [Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial](https://scholariq.org/papers/effects-of-empagliflozin-on-risk-for-cardiovascular-death-and-heart-failure/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.